Three defense orders separate advance-backed backlog from customer validation
Next Vision reported a USD 12.4 million order with advances and payment before delivery, while Veloryx and JEEN AI Tech reported smaller orders that mainly validate customer relationships. The economic difference is size, payment terms, customer quality, and whether the order repeats.
NEXT VISION reported on June 12 a USD 12.4 million order for cameras and accessories, with one advance already paid, another scheduled for June, and the remaining balance due before delivery. In the same week, VELORYX and JEEN AI TECH reported much smaller orders: one from the Ministry of Defense for Aerosol's G3 drones, and one from Gene Defense's strategic customer. This is not another broad defense-demand story, but a ranking of order quality: at NEXT VISION, the order already carries a payment path and delivery by the end of 2026; at VELORYX, the value is mostly the customer identity and validation of the acquired drone company; and at JEEN AI TECH, the second work order increases the portion already exercised under a broader engagement that still depends on future customer decisions. The three filings support the view that defense demand exists, but they are not equal in certainty, size, or financial-statement path. The next proof points are delivery and revenue recognition at NEXT VISION, follow-on orders at Aerosol, and how much of Gene Defense's optional framework becomes binding work orders.
At Next Vision, payment comes before delivery
The NEXT VISION filing is the financial anchor in this set. The company received on June 11 an order from an unrelated third party for cameras and accessories, for total consideration of approximately USD 12.4 million, excluding VAT. The customer is new, and the company expects to deliver the products by the end of the fourth quarter of 2026.
What separates this order from proof-of-capability orders is the payment schedule. About USD 544 thousand has already been paid as an advance, another approximately USD 1.937 million is due as an additional advance during June, and the remaining balance is due before product delivery. That says nothing about gross margin or production utilization, because the company does not disclose them in this filing. It does create a clearer path from order to collection and delivery.
In defense and dual-use equipment, a large order is not enough by itself. Payment terms, delivery timing, and customer identity determine whether the order adds revenue visibility or merely extends a list of expectations. Here the NEXT VISION order sits on the higher-quality side of the ladder: large amount, new customer, advances, and balance due before delivery. The remaining open issue belongs in the next reports, where delivery pace, revenue recognition, and margin contribution should become clearer.
The Ministry of Defense order validates Aerosol after the acquisition
VELORYX is at a different stage. On June 12, it reported that Aerosol, its 70%-owned subsidiary, received a binding Ministry of Defense order for G3 drones, including all components and training, for approximately NIS 1.3 million. Aerosol is required to deliver the order during 2026.
The amount is small, so the order does not change VELORYX's revenue profile by itself. Its value sits elsewhere: it comes after the company completed the acquisition of control in Aerosol on May 24, and it comes from a customer already identified in Aerosol's customer base. Before closing the acquisition, VELORYX's annual report described Aerosol as an Israeli defense company that develops, manufactures, and operates operational drone systems, with sales of NIS 16 million in 2024 and NIS 20 million in 2025, with the 2025 figures presented as unaudited.
The filing joins an earlier Ministry of Defense order published on April 23, for approximately NIS 2 million to be delivered in 2026 and 2027. Together, the two Ministry of Defense orders total about NIS 3.3 million. That is already a signal of a recurring relationship with a strong customer, but it still does not prove that Aerosol's order pace is accelerating after the acquisition. The next issue for VELORYX is not the existence of the order, but whether Aerosol keeps receiving follow-on orders and contributes enough to the consolidated reports to justify the acquisition price, the investment, and the financing used for the transaction.
At Gene Defense, the customer is exercising more of the agreement
At JEEN AI TECH, the June 10 order looks small only if read as a standalone number. Gene Defense, a wholly owned subsidiary of JEEN AI TECH, received a second work order from its strategic customer for approximately NIS 4.3 million, including VAT, for professional services around its AI platform. The services include software development, customer-specific adaptations, implementation in the customer's work environments, maintenance, and support, with completion expected by the end of 2026.
The new order brings the two work orders received from the same customer over the last three months to approximately NIS 8.6 million, including VAT. That is important progress against the March engagement, where additional work components can reach approximately NIS 45 million, but only at the customer's discretion and over 24 months from signing, until March 2028. The distinction matters: the broader potential is not the same quality as a signed work order.
JEEN AI TECH's revenue quality also needs caution. 2025 revenue was approximately NIS 9.7 million, of which 62% came from professional services and 38% from platform licensing. The Gene Defense order is meaningful relative to the company's size, but it still includes a large amount of development, customization, and implementation work. In addition, the customer agreement includes a mechanism for future payments to the customer if knowledge or outputs developed under the engagement are later sold to third parties, or if Gene Defense is sold or undergoes a change of control. That matters because part of the future value of the technology developed with the customer may be shared with the customer itself.
The recent filings also show that orders do not replace funding. On June 4, JEEN AI TECH reported a private placement of up to 6.66 million shares and about 5.33 million options to qualified investors, for up to approximately NIS 30 million, with full option exercise potentially adding dilution. The Gene Defense order improves demand validation, but by itself it is not enough to turn the activity into a recurring, profitable, self-funded revenue line.
The next read depends on delivery, repeat orders, and margins
The three filings form a clear ladder. NEXT VISION provides the order closest to revenue and collection, because it has size, pre-delivery payment, and a defined delivery window. VELORYX mainly provides customer and acquisition-asset validation, so the next read depends on repeat orders and Aerosol's contribution after consolidation. JEEN AI TECH provides another proof point that the strategic customer is using the platform, but the value still depends on how much of the optional framework becomes work orders and whether services turn into higher-quality recurring revenue.
The next few quarters will be judged in three places: whether NEXT VISION delivers and shows the contribution in upcoming reports, whether Aerosol receives follow-on orders from the Ministry of Defense and other customers, and whether Gene Defense turns more of the possible agreement into additional work orders without giving away too much of the future technology value. Until then, the local defense market is producing orders, but order quality is what separates revenue on the way to the financial statements from commercial signals that still need to accumulate.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.